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p53 mutation is the most common genetic mutation in cancer. The
mutated gene loses natural tumour suppressor function, allowing
damaged cells to divide unchecked and go on to become
malignant. Aberration of p53 has been associated with various
clinical parameters such as short survival or resistance to chemo-
and radiotherapy but there are still controverises concerning the
significance of these observations (Kirsch and Kastan, 1998;
Wallace-Brodeur and Lowe, 1999). Mutation leads to accumula-
tion of protein which acts as antigen, with subsequent develop-
ment of antibody (p53-Ab) (Davidoff et al, 1992; Soussi, 1996).
p53-Abs are directed against epitopes at the termini of the protein,
not near the core area where most mutations occur and therefore
recognize both mutant and native p53 (Schlichtholz et al, 1992;
Lubin et al, 1993).
Standardized ELISAs have been developed and large panels of
cancer patients’ sera have been tested (Angelopoulou et al, 1994;
Lubin et al, 1995a). These results have shown varying levels of
positivity for p53-Abs in all cancer types but with less than 0.5%
of healthy controls being positive. The presence of p53-Abs have
been associated with a worse prognosis in breast (Peyrat et al,
1995; Lenner et al, 1999), head and neck (Bourhis et al, 1996) and
colon cancer (Houbiers et al, 1995; Kressner et al, 1998). In
NSCLC early reports of p53 mutation suggested a variable
relationship to survival (McLaren et al, 1992; Quinlan et al, 1992;
Lee et al, 1995). Most recently p53 mutations detectable in tumour
samples have been shown to be not only an independent marker
for poor outcome in resectable stage I NSCLC (Harpole, 1995),
but also to correlate with nodal involvement and thus shorter
survival (Marchetti et al, 1993). In NSCLC there is a prevalence of
p53 antibodies of around 24% correlated with a much higher rate
of p53 mutation, of the order of 60–70% (Schlichtholz et al, 1992;
Winter et al, 1992; Wild et al, 1995; Komiya et al, 1997; Rosenfeld
et al, 1997; Bergqvist et al, 1998; Iizasa et al, 1998; Laudanski
et al, 1998; Mitsudomi et al, 1998; Segawa et al, 1998). Studies
have shown a decrease in levels of p53-Abs in patients treated for
lung cancer (Zalcman et al, 1998). p53-Ab has also been detected
before the development of clinically apparent lung cancer in 
high-risk patients (Lubin, 1995b).
In SCLC, the rate of p53 mutation is 50–75% (D’Amico et al,
1992). There have been two studies looking at p53-Abs in SCLC
which have shown a positivity rate for antibodies of the order of
16–20% (Rosenfeld et al, 1997; Zalcman et al, 2000). However,
the results of these two studies in relation to patient survival have
been contradictory, this being further examined in the discussion.
We have conducted a retrospective study on patients from The
Royal Marsden Hospital looking at serum p53-Ab expression and
survival in the largest cohort of SCLC patients treated at one
centre.
METHODS
All patients with newly diagnosed SCLC who were referred for
treatment between 1987 and 1994 and had sera stored at time of
diagnosis, before treatment commencement, were included in the
study (n = 231). Patients were staged using standard CT scanning
as either limited, with disease confined to one hemithorax, or
extensive with disease beyond one hemithorax. Staging was
performed using the current BALG and COIN guidelines, last
updated by an IASLC workshop in 1989 (Stahal et al, 1989). The
only difference in our group was that we used contralateral
supraclavicular fossa nodes to indicate extensive disease. Only
5 patients were deemed to have extensive disease purely on
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reclassified as limited. The results of the study were not changed
and thus are not shown.
Most patients received chemotherapy, which due to the long
accrual period changed greatly from single agent etoposide to
present day platinum combinations. All were entered on a database
where records of stage, WHO performance status, treatment,
response and survival were recorded. Patient response was
assessed routinely after 2 and then 4 and 6 courses and best
response was recorded.
ELISA
All sera were tested for p53-Ab by the ELISA procedure previ-
ously described (Lubin, 1995a). The results were expressed for
each serum as the ratio between the mean absorbance (optical
density at 450 nm) value of the 2 wells with p53 and the corre-
sponding wells without p53. Sera devoid of p53 antibodies were
previously shown to give a similar signal with the two extracts,
leading to a ratio of p53/control very close to 1.0. This ratio was
independent of the background of the serum.
Immunoprecipitation
To verify the specificity of ELISA for p53-Ab, we tested all
positive sera and several negative sera by immunoprecipitation
(IP) using S35 labelled p53 obtained by in vitro transcription-
translation, using the T7 TNT-coupled reticulocyte lysate method
(Promega). This has been previously described in the literature
(Zalcman et al, 2000).
Statistical methods
The characteristics of the p53 positive and negative patients were
compared by means of the chi-squared test with Yates correction
(categorical variables: sex, age, disease stage and chemotherapy
regimen), Mann-Whitney test (continuous variables: age) and the
Mann-Whitney trend test (ordered categorical variables: perfor-
mance status and response to treatment). The variables were inves-
tigated for their effect on survival using the proportional hazards
model (Cox, 1972). Survival was taken from time of diagnosis
when sera had been stored. Response to treatment was included
as a prognostic factor in the survival analysis. In all cases, the
response status (response or non-response) was first assessed after
the second course of treatment and we have therefore restricted the
response analysis to only those patients with at least 3 months
follow-up, following the landmark method. Initially a univariate
analysis of survival was done with significance assessed by the
likelihood ratio test. Hazard ratios and their 95% confidence
intervals were calculated for the various groups.
A multivariate survival analysis was done using the proportional
hazards model in order to determine whether p53 was an indepen-
dent prognostic variable after adjusting for other factors. The
proportionality assumption was checked graphically by means of
log minus log plots; proportionality could be assumed for age, sex,
performance status, chemotherapy, response and p53. For stage the
proportionality assumption was not accurate. Because of this lack
of proportionality, additional analyses were performed for limited
and extensive disease patients. A step-up procedure was used and
variables were included in the model if they were significant at the
10% 2-sided level.
RESULTS
231 patients had sera analysed for p53-Ab using a specific ELISA.
54 patients were shown to have a significant amount of p53-Ab.
All the positive sera and a series of negative sera were tested by IP
(Figure 1A). Quantification using phosphorimager indicated a
very good correlation between the two methods (Figure 1B) but
ELISA was more accurate. Of the total, 63% were male with an
overall median age of 65 (range 33–83).
With our staging criteria, 40% had limited disease. 64% of the
patients were performance status of 1 or less. Overall, p53-Abs
were detected in 23% of patients (n = 54). Patient demographics
are summarized in Table 1, further subdivided by p53 status. Of
the total group, only 3 patients remain alive to date. Age, sex,
stage, performance status, chemotherapy regime, best recorded
response and p53 status were included as variables in the
multivariate analysis.
On applying the 3-month landmark method of response to
treatment, 36 of the 231 patients were excluded. A proportionate
number of these patients were positive for p53-Ab.
In the univariate analysis, female sex, age less than 60 at presen-
tation, limited stage disease, a PS of 0 or 1, receiving a treatment
regime including platinum, or any combination as opposed to
single agent treatment were all significant predictors of survival.
(Table 2). p53 status was not significant. However, the computer
statistical package still included it as a multivariate analysis field
due to the bias of a higher proportion of p53-positive patients
having ED as compared to those negative for the antibody (65% vs
58%).
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Table 1 Patient characteristics according to p53 status – overall
P53 status +ve –ve Total Sig
Patients 54 177 231
Age Median (range) 64 (33–83) 65 (35–79) 65 (33–83) 0.5a
Sex M : F 33 : 21 113 : 64 146 : 85 0.8b
PS 0/1/2/3 4/29/16/4 17/98/45/15 21/127/62/19 0.5c
Chemotherapy
Platinum 30 90 120 0.9b
Other combo 14 45 59
Single agent 10 38 48
No 0 4 4
Response CR / PR / NR 7 / 30 / 17 25 / 105 / 42 32 / 135 / 59 0.4c
Stage LD / ED 19 / 35 74 / 103 93 / 138 0.5b
aMann-Whitney test. bChi-square test with Yates correction. c Mann-Whitney test for trend across groups.With multivariate analysis of the overall group, limited stage
disease, a PS of 0 or 1 and response to treatment were all indepen-
dently significant predictors of survival. Platinum combination
chemotherapy also conferred an overall survival advantage. After
adjustment for all these factors, p53 status appeared also as an
independent prognostic factor (P = 0.02; Figure 2). Using an index
level of ELISA of 5 or greater as a level of strong positivity,
having a detectable level of p53 antibody was associated with
a survival advantage, having a median survival of 11 months vs
8 months in those patients with no antibody production. Taking
this absorbance level excluded 20 patients (11 ED and 9 LD) with
low levels of positivity, with a proportion of these having doubtful
significance. These are summarized in Table 3.
When the patients were divided into limited and extensive
disease and analysed separately, in patients with limited disease
there was a trend towards improved survival in female patients and
those with p53-Ab (Table 4a – multivariate of LD). In the analysis
of extensive disease alone, a PS of 0 or 1, response to treatment,
platinum containing combination treatment and p53-Ab positivity
were independently significant (Table 4b – multivariate of ED).
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Figure 2 Kaplan-Meier survival curve showing relation of high titre (>5) as
compared to a low (<5) or negative p53-Ab level. The curve is significant with
a P value of 0.02
Figure 1 Immunoprecipitation of in vitro translated p53 with sera from
patients with lung cancer. p53 was precipitated with sera which were
previously analysed by ELISA. Sera were divided in 3 classes depending on
their reactivity. High and low were positive by ELISA. The threshold between
the 2 classes was a ratio value of 5 (see Material and methods); (A)
autoradiogram; (B) quantification analysis using phosphoimager. Ng:
negative sera from a healthy blood donor; In: input of p53 protein used for the
immunoprecipitation (10%); control immunoprecipitation with a monoclonal
antibody specific for human p53 (HR231).
Table 2 Univariate analysis of survival – all patients
Variable Group RR of death 95% CI Significance – Cox
(P)
Sex Male 1.0
Female 0.75 0.57–0.98 0.04
Age ≤ 60 1.0
≥ 60 1.33 1.01–1.76 0.04
Stage Limited 1.0
Extensive 2.03 1.54–2.69 <0.001
PS 0 and 1 1.0
2, 3 and 4 1.87 1.42–2.46 <0.001
Chemo Platinum 1.0
No platinum 1.44 1.11–1.88 0.006
Combination 1.0
Single agent 1.51 1.10–2.08 0.02
Response CR 1.0
Not CR 2.12 1.44–3.12 <0.001
Any response 1.0
No response 1.86 1.38–2.51 <0.001
p53 status +ve 1.0
–ve 1.17 0.78–1.46 0.5
+ve ≥ 5 1.0
–ve or <5 1.32 0.92–1.91 0.1When we restricted the analysis to just those patients who had
received platinum containing regimens (our current practice), the
effect of p53 was no longer significant (Table 4c). However, this
may be due to small numbers with just 13 (11%) of these patients
having a p53-Ab titre of greater than 5.
DISCUSSION
In this, the largest study so far looking at p53-Ab in SCLC there
was no significant correlation between the presence of antibody
and clinical outcome. However, when we used a cut off of the
ELISA index absorbance of greater than 5 to indicate strong
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Table 3 Multivariate analysis of survival – all patients
Variable Group RR of death 95% CI Significance – Cox
(P)
Stage Limited 1.0
Extensive 2.66 1.54–2.78 <0.001
Response Any response 1.0
No response 1.80 1.31–2.46 <0.001
CR 1.0
Not CR 1.70 1.13–2.54 0.004
PS 0 and 1 1.0
2, 3 and 4 1.92 1.44–2.55 <0.001
p53 High (≥ 5) 1.0
–ve or <5 1.57 1.08–2.28 0.02
Chemo Platinum combination 1.0
Other 1.39 1.06–1.82 0.02
Table 4a Multivariate analysis of survival – limited stage only
Variable Group RR of death 95% CI Significance – Cox
(P)
Response CR 1.0
Not CR 1.91 1.15–3.18 0.02
p53 status High (≥ 5) 1.0
–ve or <5 1.88 0.97–3.66 0.04
Table 4b Multivariate analysis of survival – extensive stage only
Variable Group RR of death 95% CI Significance – Cox
(P)
Response Any response 1.0
No response 2.54 1.69–3.81 <0.001
CR 1.0
Not CR 2.58 1.29–5.19 0.003
PS 0 and 1 1.0
2, 3 and 4 2.71 1.84–3.98 <0.001
Chemo Platinum combn 1.0
Other 1.67 1.16–2.39 0.009
p53 status High (≥ 5) 1.0
–ve or <5 1.67 1.05–2.68 0.02
Table 4c Multivariate analysis of survival – patients receiving platinum combination
Variable Group RR of death 95% CI Significance – Cox
(P)
Stage Limited 1.0
Extensive 2.02 1.32–3.07 <0.001
PS 0 and 1 1.0
2,3 and 4 1.86 1.21–2.84 0.01
Response Any response 1.0
No response 1.72 1.06–2.77 0.03
P53 status High (≥ 5) 1.0
–ve or <5 1.53 0.83–2.82 0.2positivity and to avoid possible sampling error, p53-Ab positivity
appears to be associated with a longer survival. Dividing the
groups into limited and extensive disease, strong p53-Ab posi-
tivity was still significant as a predictor for longer survival. Using
this higher index level the percentage of patients from the overall
group with this level of antibody decreased from 23% to 15%.
The presence of p53-Ab, often reflecting p53 mutation, has
been associated with poor prognosis and shorter survival in
NSCLC (Quinlan et al, 1992; Marchetti et al, 1993; Harpole et al,
1995; Laudanski et al, 1998). Some groups have found no such
correlation (McLaren et al, 1992; Mitsudomi et al, 1998) and
others have shown a favourable prognosis (Lee et al, 1995;
Bergqvist et al, 1998). P53 in SCLC has not been studied as exten-
sively, but there are two large studies that we can compare our
results with. Work by Zalcman et al (2000) on a French patient
cohort from four hospitals in Paris has shown that the presence of
p53-Ab, detected with ELISA and IP, bore no relation to survival.
The other study by Rosenfeld et al (1997), using only Western
blotting, also showed no correlation. When Zalcman et al (2000)
divided their patients into limited and extensive stage, p53-Ab
positivity emerged as an independent marker of poor prognosis in
limited disease. Table 5 shows the numbers of p53 positive and
negative patients with limited stage disease in each of the three
studies, indicating a comparable division of patients numbers, all
being small, possibly affecting statistical analysis. In Table 6 we
have summarized the main differences in patient data for all three
studies.
The behaviour of p53-Abs toward the tumour is so far unclear. It
is generally believed that these antibodies are totally opportunist,
reflecting p53 mutation and accumulation. Their clinical value
could be associated with p53 loss of function, rather than immune
modulation. It is conceivable that such antibodies, together with a
T cell response, could enhance the destruction of the tumour in
response to treatment. We know that SCLC tumours are very
sensitive to both chemo- and radiotherapy, with patients usually
having a good initial response, though often relapsing later. The
high level of apoptosis of tumour cells during therapy, with the
release of free p53 protein, could lead to a potential immunolog-
ical boost inside the tumour. Patients with an elevated p53 humoral
response could use such an immune response to destroy residual
neoplastic cells in the primary tumour. Such a hypothesis is
supported by experiments demonstrating that immunization with
entire p53 can lead to protection toward p53 expressing tumour
(Roth et al, 1996).
The p53-Ab has been shown to be directed against epitopes in
the p53 protein that are not affected by mutation and is only
produced where there is substantial antigen accumulation. Thus,
theoretically, an antibody response could be mounted against wild-
type p53 which has accumulated in the cell and been released once
apoptosis and cell damage have occurred.
Tumours with p53 mutation can be more rapidly growing, as
they have escaped from the usual cell cycle growth check-points,
resulting in more tumour cell death by apoptosis or necrosis. In our
group proportionally more patients with p53-Ab had extensive
disease, this reflecting a greater tumour burden. Despite this these
patients appear to have a survival advantage. Thus, the presence of
p53 mutation could actually mediate for a better chemotherapy
response. This has been shown by other groups in ovarian (Cote
et al, 1997) and colorectal cancer (Waldman et al, 1996).
It has also been shown that not all mutant p53 proteins lose
complete function and might retain the ability to induce apoptosis
and cell death (Levine et al, 1994). Most of our samples are from
over a long period of time and tumour tissues are not available for
mutation analysis. We are, however, presently looking at some
selected tissue samples in the panel.
Looking further at the univariate analysis there appears to be a
survival advantage for the female subgroup. As shown in Table 6,
our group had a higher proportion of female patients than previous
studies, 85 (37%) of the total, perhaps reflecting the higher
number of female smokers in the UK. It is known that female lung
cancer rates are on the increase whereas incidence in males is
plateauing off (Zang and Wynder, 1996). The only difference
between the male and female groups were that the females were
younger, with the median age of males being 66 compared to 63
for females (P = 0.02). There was a trend for the females to have
LD (45% of the total, P = 0.06). Whether this reflected a different
presentation of females with lung cancer, or just that the females
being younger did better overall, is not clear.
Another division of the patients was into groups having
received differing chemotherapy regimes. Recent studies have
looked at the role of p53 mutation in chemotherapeutic resistance
(Fritsche et al, 1993), particularly to cisplatin (Rusch et al, 1995).
Over this 8-year period our patients received several different regi-
mens, though we were particularly interested in those that
contained platinum, along with those that received single agent
treatment as opposed to any combination. In the same overall
multivariate analysis any platinum combination therapy was seen
to be superior to other treatments (P = 0.04), as previously shown
in randomized trials (Girling, 1996). Previous studies have
reported the advantages of a platinum-based regimen in SCLC
(Einhorn et al, 1988; Fukuoka et al, 1991).
In summary, this homogenous population of SCLC patients, the
largest group looked at so far, were all treated in one Oncology
Centre. We have shown that in our group, high titres of p53 anti-
body appear to confer an overall survival advantage. We have also
shown in this same group that female sex and/or younger age
(<60 years) appears to carry some survival benefit. Receiving a
platinum-based treatment regimen also appears to be beneficial.
We are presently looking at a group of these patients who had
serial sera samples taken during treatment to try and relate changes
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Table 5 Characteristics of LD in SCLC p53 studies
Murray (2000) Zalcman (1999) Rosenfeld (1997)
UK France Spain
No LD 93 54 70
(% of total) (40) (56) (41)
No p53 +ve 19 13 12
(% of LD) (20) (24) (17)
Table 6 Data comparisons between SCLC p53 studies
Variable Murray (2000) Zalcman (1999) Rosenfeld (1997)
UK France Spain
No 231 97 170
Females (%) 37 18 5
Pts under age 60 (%) 27 56 39
LD (%) 40 56 41
Platinum Rx (%) 52 100 55
Complete response (%) 14 40 25
P53 positivity (%) 23 (15) 20.6 16Serum p53 antibodies in SCLC 1423
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in p53 antibody levels to any treatment response. We are also
looking at the original tumour tissue samples in these patients to
correlate tissue p53 mutation with sera antibody production.
In conclusion, this study suggests that p53-Ab detection in
SCLC patients’ sera could be clinically useful as it may help to
predict those patients that may do better.
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